Sellas Life Sciences is trading 4.01% lower at $11.54, primarily amid broad U.S. equity weakness on September 23, 2026. - The Nasdaq fell 1.02%, the S&P 500 0.64%, and the Dow 0.66%; rising Treasury yields and renewed oil-driven inflation concerns pressured risk assets. - No new company-specific announcement clearly explains the intraday decline. - Delayed Phase 3 Galinpepimut-S results remain a negative overhang, though global risk-off trading is the primary explanation.